SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9
http://www.w3.org/2000/01/rdf-schema#comment
"CD164 was associated with the poor clinical outcomes of BC patients. Silencing of CD164 could inhibit the progression of tumors in vivo and in vitro which may become an effective target in the treatment of bladder cancer."
xsd:string
http://purl.uniprot.org/uniprot/#_0FF43260E9588826740F699D6CF7F1358E4E2DD89A0D519BA61BE92894763B9151382E0650960BA84DCFAF1FE407E831
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9
http://purl.uniprot.org/uniprot/D6R9B4
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9
http://purl.uniprot.org/uniprot/#_D6R9B4-mappedCitation-30022623
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/8A9B8506A04082387C6C7EDD1104107C5A650BA6877FE26A8E46453EC9B2655252D9C20817E4A0B5AFE338ADCF0BABF9